Sedana Medical

Focus: Sedana Medical is a Swedish-based biotechnology company specializing in anesthetic conserving devices for intensive care medicine. The company operates as a public entity with a focused pipeline in inhaled anesthetics and sedation therapies.

Intensive Care Medicine Intensive care

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Sedana Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Sedana Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Isoflurane

Sedation

N/A

Clinical Trials (1)

NCT07457593Expanded Access for Inhaled Isoflurane Delivered Via the Sedaconda ACD-S for Sedation of Difficult-to-Sedate Adult Mechanically Ventilated Intensive Care Unit Patients

N/A

Help build intelligence for Sedana Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline focused on Phase 3 programs with 5 active late-stage trials in sedation and critical care indications, offering clear near-term regulatory catalysts
Public company status provides equity upside potential and transparent financial/strategic direction versus private biotech
Specialized focus on intensive care medicine addresses high-unmet need in post-ICU recovery and acute respiratory distress syndrome

Watch Out For

Only 2 active job openings signals minimal hiring activity and limited near-term career growth opportunities
Extremely limited public information on financials, workforce size, R&D spend, and cash position creates uncertainty around company stability and compensation

Generated by Claude from Sedana Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Propofol

Acute Respiratory Distress Syndrome

Phase 2/3

Clinical Trials (1)

NCT06014138Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome

Phase 2/3

Isoflurane

Sedation

Phase 3

Clinical Trials (1)

NCT05312385Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)

Phase 3

Inhaled isoflurane administered by Sedaconda ACD-S

Post-Intensive Care Syndrome

Phase 3

Clinical Trials (1)

NCT06809218A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous Propofol

Phase 3

Isoflurane

Sedation

Phase 3

Clinical Trials (1)

NCT05327296Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)

Phase 3

Midazolam

Sedation

Phase 3

Clinical Trials (1)

NCT04684238Effect & Safety of Inhaled Isoflurane vs IV Midazolam for Sedation in Mechanically Ventilated Children 3-17 Years Old

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Top TAs: Respiratory

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Respiratory

1 pipeline

Marketed

Pipeline